A predicting model of bone marrow malignant infiltration in 18F-FDG PET/CT images with increased diffuse bone marrow FDG uptake
Mingge Zhou, Yumei Chen, Jianjun Liu, Gang Huang, Mingge Zhou, Yumei Chen, Jianjun Liu, Gang Huang
Abstract
Purpose: To demonstrate the relationship between the etiologies of increased diffuse bone marrow (BM) 18F-FDG uptake and PET/CT imaging/clinical features, as well as to explore a predicting model of BM malignant infiltration (MI) based on decision tree. Methods: 84 patients with increased diffuse BM uptake were retrospectively enrolled. Their complete case record and PET/CT images were reviewed, with the maximal standardized uptake values of bone marrow (SUVmaxBM) and other imaging/clinical features were noted. At the same time, the differences in imaging/clinical features between bone marrow MI and non-MI groups were compared. The decision tree for predicting MI was established by C5.0 component of SPSS Clementine. Results: In patients with homogenously increased BM uptake, 21 patients had MI resulted from leukemia, lymphoma and small cell lung cancer (SCLC). MI group had higher SUVmaxBM than non-MI group (6.7±3.1 vs 4.2±0.9, p=0.001). However, a considerable proportion of MI patients had similar SUVmaxBM to non-MI patients, which were mainly seen in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia (LPL/WM), chronic myeloid leukemia (CML) and multiple myeloma (MM). There were significant differences in other factors between the two groups. MI patients were highly associated with SUVmaxAP/AX≥1 (the ratio of SUVmaxBM of appendicular skeleton to that of axial skeleton), hepatosplenomegaly, older age and lower rate of fever. The decision tree combining SUVmaxBM, SUVmaxAP/AX, fever and hepatosplenomegaly achieved a sensitivity of 81.0%, a specificity of 98.4% and an accuracy of 94.0% for predicting MI. Conclusion: Increased diffuse BM 18F-FDG uptake can be attributed to both bone marrow MI and benign etiologies. A decision tree based on C5.0 algorithm, combining PET/CT imaging and clinical features, is of potential use in discriminating BM malignant infiltration from patients with increased diffuse BM uptake.
Keywords: PET/CT; SUVmax; bone marrow; malignant infiltration; predicting model.
Conflict of interest statement
Competing Interests: The authors have declared that no competing interest exists.
Figures
References
- Akin O, Brennan SB, Dershaw DD. et al. Advances in oncologic imaging: update on 5 common cancers. CA: a cancer journal for clinicians. 2012;62:364–93.
- Chiang SB, Rebenstock A, Guan L. et al. Diffuse bone marrow involvement of Hodgkin lymphoma mimics hematopoietic cytokine-mediated FDG uptake on FDG PET imaging. Clinical nuclear medicine. 2003;28:674–6.
- Elstrom RL, Tsai DE, Vergilio J-A. et al. Enhanced Marrow [18F]Fluorodeoxyglucose Uptake Related to Myeloid Hyperplasia in Hodgkin's Lymphoma Can Simulate Lymphoma Involvement in Marrow. Clinical Lymphoma. 2004;5:62–4.
- Takalkar A, Yu JQ, Kumar R. et al. Diffuse bone marrow accumulation of FDG in a patient with chronic myeloid leukemia mimics hematopoietic cytokine-mediated FDG uptake on positron emission tomography. Clinical nuclear medicine. 2004;29:637–9.
- Su K, Nakamoto Y, Nakatani K. et al. Diffuse homogeneous bone marrow uptake of FDG in patients with acute lymphoblastic leukemia. Clinical nuclear medicine. 2013;38:e33.
- Salaun PY, Gastinne T, Bodet-Milin C. et al. Analysis of 18F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin's lymphoma: a reflection of disease infiltration or just inflammation? European journal of nuclear medicine and molecular imaging. 2009;36:1813–21.
- Blodgett TM, Ames JT, Torok FS. et al. Diffuse bone marrow uptake on whole-body F-18 fluorodeoxyglucose positron emission tomography in a patient taking recombinant erythropoietin. Clinical nuclear medicine. 2004;29:161.
- Yi C, Shi X, Wang X. et al. The alteration of 18F-FDG uptake in bone marrow after treatment with interleukin 11. Clinical nuclear medicine. 2014;39:934.
- Kang BW, Lee YJ, Chae YS. et al. Prognostic impact of bone marrow involvement for patients with diffuse large B-cell lymphoma in the era of rituximab. Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology. 2011;29:e18514.
- Braun S, Vogl FD, Pantel K. Presence of bone marrow micrometastasis (BMM) in breast cancer patients predicts a poor-prognosis pattern of first distant metastasis: Results from the pooled analysis. Journal of Clinical Oncology. 2006;45:351–2.
- Alam MS, Fu L, Ren YY. et al. 18F-FDG super bone marrow uptake: A highly potent indicator for the malignant infiltration. Medicine. 2016;95:e5579.
- Bain BJ. Morbidity associated with bone marrow aspiration and trephine biopsy - a review of UK data for 2004. Haematologica. 2006;91:1293–4.
- Frey L, Edgerton ME, Fisher DH, Using prior knowledge and rule induction methods to discover molecular markers of prognosis in lung cancer. Amia Annu Symp Proc; 2004. pp. 256–60.
- Delorme S, Baur-Melnyk A. Imaging in multiple myeloma. European journal of radiology. 2009;70:401–8.
- Elena Z, Cristina N, Francesca P. et al. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica. 2007;92:50.
- Chen YK, Yeh CL, Tsui CC. et al. F-18 FDG PET for evaluation of bone marrow involvement in non-Hodgkin lymphoma: a meta-analysis. Clinical nuclear medicine. 2011;36:553–9.
- Nakajo M, Jinnouchi S, Inoue H. et al. FDG PET findings of chronic myeloid leukemia in the chronic phase before and after treatment. Clinical nuclear medicine. 2007;32:775.
- Sachpekidis C, Mai EK, Goldschmidt H. et al. (18)F-FDG dynamic PET/CT in patients with multiple myeloma: patterns of tracer uptake and correlation with bone marrow plasma cell infiltration rate. Clinical nuclear medicine. 2015;40:300–7.
- Arimoto MK, Nakamoto Y, Nakatani K. et al. Increased bone marrow uptake of 18F-FDG in leukemia patients: preliminary findings. SpringerPlus. 2015;4:521.
- Inoue K, Goto R, Okada K. et al. A bone marrow F-18 FDG uptake exceeding the liver uptake may indicate bone marrow hyperactivity. Annals of nuclear medicine. 2009;23:643–9.
- Cheng G. Using a cut-off SUV level to define bone marrow lesions on FDG PET is not appropriate. Annals of hematology. 2013;92:283–4.
Source: PubMed